68 Plaque Psoriasis (Country) Market Analysis And Sales Forecast To 2030

(MENAFN- GlobeNewsWire - Nasdaq) The Plaque Psoriasis market is set for significant growth, driven by a rising diagnosis rate and five new drug launches. Key opportunities lie in therapeutic advancements and strategic partnerships across major markets like the US, Europe, and Japan, which dominate sales. Competitive landscape insights and pipeline assessments are crucial for strategic planning.

Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: 68-Market Analysis and Sales Forecast - Update (2025)" report has been added to ResearchAndMarkets's offering.

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Plaque Psoriasis (PsO) market through 2030.
The analyst estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $30.1 billion, representing a compound annual growth rate (CAGR) of 10.0% over the 10-year forecast period. Major drivers of growth in the PsO market over the forecast period include a steady increase in total diagnosed prevalence across the 7MM and launches of five new pipeline agents: icotrokinra (JNJ-2113), sonelokimab, orismilast, piclidenoson, and TAK-279.

Across the 68 markets, sales in the PsO market were in 2020, growing to $44.0 billion in 2030. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 70.5% and 68.4% of 68-market sales in 2020 and 2030, respectively.
Scope

• Overview of Plaque Psoriasis (PsO), including epidemiology, symptoms, diagnosis, and disease management.
• Annualized Plaque Psoriasis (PsO) therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PsO therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PsO treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global Plaque Psoriasis (PsO) therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM and 68M Plaque Psoriasis (PsO) therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM and 68M Plaque Psoriasis (PsO) therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Topics Covered:
1 Executive Summary
1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders and payers interviewed for this report
2.3.1 Key opinion leaders
2.3.2 Payers
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Therapy Area Director
2.5.3 Epidemiologist
2.5.4 Epidemiology reviewers
2.5.5 Vice President of Disease Intelligence and Epidemiology
2.5.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
Companies Featured

• Amgen Inc
• Organon
• Leo Pharmaceuticals
• Arcutis Biotherapeutics
• AbbVie
• BMS
• Janssen
• Johnson & Johnson
• Novartis
• UCB
• AstraZeneca
• Sun Pharma
• Bausch Health
• Union Therapeutics
• Can-Fite Biopharma
• Alumis
• Lilly
• Takeda
• MoonLake Immunotherapeutics
• Bristol-Myers Squibb Co
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Co Ltd
• Sanofi
• AbbVie Inc
• UCB Inc
• Johnson and Johnson, Inc.
• Union Therapeutics AS
• Janssen
• LEO Pharma
• Dermavant Sciences Inc
• Arcutis Biotherapeutics Inc
• MoonLake Immunotherapeutics
• Bausch Health

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN10092025004107003653ID1110043619